Early Detection of Epstein-Barr Virus as a Risk Factor for Chronic High Epstein-Barr Viral Load Carriage at a Living-donor-dominant Pediatric Liver Transplantation Center

• Published in: Transplantation Vol. 107; no. 6; p. 1322
• Main Authors: Yamada, Masaki, Fukuda, Akinari, Ogura, Miyuki, Shimizu, Seiichi, Uchida, Hajime, Yanagi, Yusuke, Ishikawa, Yuriko, Sakamoto, Seisuke, Kasahara, Mureo, Imadome, Ken-Ichi
• Format: Journal Article
• Language: English
• Published: United States 01.06.2023
• Subjects: Child; DNA, Viral; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Liver Transplantation - adverse effects; Living Donors; Lymphoproliferative Disorders; Risk Factors; Viral Load
• ISSN: 1534-6080
• DOI: 10.1097/TP.0000000000004429

Epstein-Barr virus (EBV) infection and posttransplant lymphoproliferative disorders (PTLDs) after pediatric liver transplantation (LT) account for significant morbidity and mortality. Knowledge of EBV kinetics, epidemiology, and outcomes among pediatric living-donor LT cases is largely lacking. This study aims to provide clinical information related to EBV infection, chronic high EBV load (CHL) carriage, and PTLD at a living-donor-dominant pediatric LT center. A total of 5827 EBV load measurements from 394 LT recipients fulfilling inclusion criteria and their clinical data were analyzed. EBV loads >1000 copies/μg DNA (742 IU/μg DNA) were considered "high," and CHL was defined by persistence >6 mo. The highlighted results were as follows: (1) 94% of recipients underwent living-donor LT; (2) 80% of EBV seronegative recipients developed first EBV infection <2 y post-LT, and their EBV loads were consistently higher than those of seropositive recipients within <3 y post-LT but did not differ thereafter; (3) 61 (15%) recipients met CHL criteria, but none developed PTLD; (4) age <5 y, cytomegalovirus seronegative donors, and early development of EBV DNAemia <6 mo post-LT were independent risk factors for CHL; (5) the incidence of rejections after 1-y post-LT was comparably low among CHL carriers whose immunosuppression was minimized. Early detection of EBV following LT and CMV seronegative donors would facilitate risk stratification to prevent PTLD while titrating immunosuppression among pediatric LT recipients.